Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

This study is testing a new drug called tegavivint in patients with colorectal cancer that has spread and has not responded to multiple prior treatments. Tegavivint works by targeting a specific cancer-promoting protein pathway (called the Wnt/beta-catenin pathway). **You may be eligible if...** - You are 18 years or older - You have colorectal cancer that has spread (metastatic) and has been confirmed by biopsy - You have already tried at least 2 standard chemotherapy regimens including fluoropyrimidine, oxaliplatin, irinotecan, and an anti-VEGF drug - Your cancer's genetic profile (RAS, BRAF, MSI/MMR status) has been tested - You are well enough to participate (ECOG performance status 0–1) **You may NOT be eligible if...** - You have a different type of colorectal cancer (not adenocarcinoma) - You have significant organ dysfunction - You have not tried the required prior therapies Talk to your doctor to see if this trial is right for you.